Login
Companies $COR
$356.94 +$0.00 (0.0%) After hours
Cencora, Inc. logo

Cencora, Inc.

cencora.com

What Do They Do?

Distributes medicines, healthcare products and related services to healthcare providers and pharmaceutical manufacturers.

How Do They Make Money?

Cencora earns most of its revenue by distributing pharmaceuticals and related products: customers pay when ownership passes to them. Service fees are earned over the period services are provided, while manufacturer fees are earned as the service is performed.

FY2025 revenue by reportable segment revenue
SegmentShareRevenue
U.S. Healthcare Solutions
Sold outright

89%
FY2022: 89%
International Healthcare Solutions
8.8%
FY2022: 11%

Who Are Their Customers?

Healthcare providers—including hospitals, pharmacies, clinics, physicians and veterinarians—and pharmaceutical manufacturers buy Cencora's products and services; it is typically the primary supplier to provider customers.

Customers above 10% of revenue, FY2025
of revenue from two customers (25%, 13%)

Do Revenues Turn Into Profits?

Yes. It kept less than a cent of every revenue dollar as net income in FY2025 and turned 1 cent into free cash flow.

Operating income, FY2025
1% of revenue
▲ +21% vs FY2024 ($2.2B, 1%)
Net income, FY2025
0% of revenue
▲ +3% vs FY2024 ($1.5B, 1%)
Free cash flow, FY2025
1% of revenue
▲ +7% vs FY2024 ($3B, 1%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Jun 30, 2026
Revenue
▲ +5%
vs $80.7B in Q3 FY2025
Net income
▲ +11%
vs $687.4M in Q3 FY2025
U.S. Healthcare Solutions share of revenue vs 88.5% in Q3 FY2025
  • May 29, 2026 Named Eva Boratto chief financial officer and reaffirmed fiscal 2026 guidance She succeeds James Cleary, who is retiring; the company reaffirmed its adjusted earnings per share outlook.
  • Mar 23, 2026 Agreed to acquire EyeSouth Partners’ retina business The retina physicians would join Retina Consultants of America; the deal awaits customary closing conditions, including regulatory approvals.

Growing. Revenue grew 50% in 4 years, from $214B in FY2021 to $321.3B in FY2025, about 11% a year.

Expanded international life-sciences services The latest report describes regulatory, market-access, drug-safety, development and quality services as part of International Healthcare Solutions; the older report described these PharmaLex services as part of a planned acquisition.

Revenue over time
U.S. Healthcare Solutions International Healthcare Solutions
$500B$250B$0

Who Do They Compete With?

Competes with McKesson, Cardinal Health, and UPS Logistics

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support